RxDoctor Payments Data

Syed Hassan, MD

Hematology & Oncology · Saginaw, MINPI 1992748701

Payments from drug & device makers

$912in general payments, 2019–2025

Across 41 payments — averaging $22.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$113
  • Seagen Inc.$87
  • Merck$85
  • Karyopharm Therapeutics Inc.$77
  • Genentech USA, Inc.$72
  • AstraZeneca$62
  • plus $416 from 16 others

What the payments were for

  • Food & beverage$85293%
  • Education$607%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$912 in reported general payments places this provider in the 35th percentile of 282 hematology & oncology providers in Michigan.

See all hematology & oncology providers in Michigan

Medicare billing

Part B allowed, 2024
$107,959
Medicare patients
334
Services billed
1,037

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib22$468,487
TagrissoOsimertinib Mesylate29$465,381
Abiraterone Acetate65$260,646
Lenalidomide14$224,687
JakafiRuxolitinib Phosphate15$222,939
XtandiEnzalutamide16$221,133
KisqaliRibociclib Succinate15$210,664
IbrancePalbociclib11$165,343
Everolimus12$91,560
Imatinib Mesylate35$68,924
Anastrozole581$25,381
EliquisApixaban33$25,142
Exemestane31$9,782
Letrozole148$9,274
Prochlorperazine Maleate144$2,955

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso$62$465,38129 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$13$260,64665 claims
Incyte CorporationJakafi$27$222,93915 claims
Astellas Pharma US IncXtandi$24$221,13316 claims
PfizerIbrance, Eliquis$11$190,48544 claims
Lilly USA, LLCOlanzapine$17$8617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 282 hematology & oncology providers in Michigan.

Other hematology & oncology in Saginaw

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →